Evaluation of Pancreatic Cancer Specimens for Comprehensive Genomic Profiling

Overview

Journal Pathol Int

Specialty Pathology

Date 2024 Mar 13

PMID 38477638

Authors

Kota Washimi

Yukihiko Hiroshima

Shinya Sato

Makoto Ueno

Satoshi Kobayashi

Naoto Yamamoto

Chie Hasegawa

Emi Yoshioka

Kyoko Ono

Yoichiro Okubo

Tomoyuki Yokose

Yohei Miyagi

Affiliations

Soon will be listed here.

Abstract

Inadequate specimen quality or quantity hinders comprehensive genomic profiling in identifying actionable mutations and guiding treatment strategies. We investigated the optimal conditions for pancreatic cancer specimen selection for comprehensive genomic profiling. We retrospectively analyzed 213 pancreatic cancer cases ordered for comprehensive genomic profiling and compared results from pancreatic biopsy, liver biopsy of pancreatic cancer metastases, pancreatectomy, liquid, and nonliver metastatic organ specimens. We examined preanalytical conditions, including cellularity (tumor cell count/size). The successfully tested cases were those that underwent comprehensive genomic profiling tests without any issues. The successfully tested case ratio was 72.8%. Pancreatic biopsy had the highest successfully tested case ratio (87%), with a high tumor cell percentage, despite the small number of cells (median, 3425). Pancreatic biopsy, liver biopsy of pancreatic cancer metastases, and non-liver metastatic organ had higher successfully tested case ratios than that for pancreatectomy. Liver biopsy of pancreatic cancer metastases and pancreatectomy cases with tumor size (mm) × tumor ratio (%) > 150 and >3000, respectively, had high successfully tested case ratios. The success of comprehensive genomic profiling is significantly influenced by the tumor cell ratio, and pancreatic biopsy is a potentially suitable specimen for comprehensive genomic profiling.

Citing Articles

Primary omental smooth muscle tumor in an adult male: a diagnostic dilemma for leiomyoma: a case report.

Ono Y, Okubo Y, Washimi K, Mikayama Y, Doiuch T, Hasegawa C J Med Case Rep. 2024; 18(1):222.

PMID: 38704583 PMC: 11070120. DOI: 10.1186/s13256-024-04537-9.

Evaluation of pancreatic cancer specimens for comprehensive genomic profiling.

Washimi K, Hiroshima Y, Sato S, Ueno M, Kobayashi S, Yamamoto N Pathol Int. 2024; 74(5):252-261.

PMID: 38477638 PMC: 11551823. DOI: 10.1111/pin.13416.

References

Evans D, Rich T, Byrd D, Cleary K, Connelly J, Levin B . Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992; 127(11):1335-9. DOI: 10.1001/archsurg.1992.01420110083017. View

Zarkavelis G, Kotoula V, Kolliou G, Papadopoulou K, Tikas I, Karavasilis V . Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group.... ESMO Open. 2019; 4(5):e000525. PMC: 6802956. DOI: 10.1136/esmoopen-2019-000525. View

Greer C, Lund J, Manos M . PCR amplification from paraffin-embedded tissues: recommendations on fixatives for long-term storage and prospective studies. PCR Methods Appl. 1991; 1(1):46-50. DOI: 10.1101/gr.1.1.46. View

McCutcheon J, Giaccone G . Next-Generation Sequencing: Targeting Targeted Therapies. Clin Cancer Res. 2015; 21(16):3584-5. DOI: 10.1158/1078-0432.CCR-15-0407. View

Kanagal-Shamanna R, Portier B, Singh R, Routbort M, Aldape K, Handal B . Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol. 2013; 27(2):314-27. DOI: 10.1038/modpathol.2013.122. View

Gillen S, Schuster T, Zum Buschenfelde C, Friess H, Kleeff J . Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010; 7(4):e1000267. PMC: 2857873. DOI: 10.1371/journal.pmed.1000267. View

Khoury T . Delay to Formalin Fixation (Cold Ischemia Time) Effect on Breast Cancer Molecules. Am J Clin Pathol. 2018; 149(4):275-292. DOI: 10.1093/ajcp/aqx164. View

Hasegawa C, Washimi K, Hiroshima Y, Kasajima R, Kikuchi K, Notomi T . Differential diagnosis of uterine adenosarcoma: identification of JAZF1-BCORL1 rearrangement by comprehensive cancer genomic profiling. Diagn Pathol. 2023; 18(1):5. PMC: 9837955. DOI: 10.1186/s13000-022-01279-4. View

Chen H, Luthra R, Goswami R, Singh R, Roy-Chowdhuri S . Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies. Cancers (Basel). 2015; 7(3):1699-715. PMC: 4586792. DOI: 10.3390/cancers7030859. View

10.

Washimi K, Hiroshima Y, Sato S, Ueno M, Kobayashi S, Yamamoto N . Evaluation of pancreatic cancer specimens for comprehensive genomic profiling. Pathol Int. 2024; 74(5):252-261. PMC: 11551823. DOI: 10.1111/pin.13416. View

11.

Sugiyama K, Washimi K, Sato S, Hiruma T, Sakai M, Okubo Y . Differential diagnosis of lipoma and atypical lipomatous tumor/well-differentiated liposarcoma by cytological analysis. Diagn Cytopathol. 2022; 50(3):112-122. PMC: 9305447. DOI: 10.1002/dc.24928. View

12.

Pant S, Weiner R, Marton M . Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol. 2014; 4:78. PMC: 4029014. DOI: 10.3389/fonc.2014.00078. View

13.

Nagahashi M, Shimada Y, Ichikawa H, Nakagawa S, Sato N, Kaneko K . Formalin-fixed paraffin-embedded sample conditions for deep next generation sequencing. J Surg Res. 2017; 220:125-132. PMC: 5726294. DOI: 10.1016/j.jss.2017.06.077. View

14.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

15.

Frampton G, Fichtenholtz A, Otto G, Wang K, Downing S, He J . Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31(11):1023-31. PMC: 5710001. DOI: 10.1038/nbt.2696. View

16.

Khalifa A, Rockey D . The utility of liver biopsy in 2020. Curr Opin Gastroenterol. 2020; 36(3):184-191. PMC: 10874678. DOI: 10.1097/MOG.0000000000000621. View

17.

Young G, Wang K, He J, Otto G, Hawryluk M, Zwirco Z . Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol. 2013; 121(12):688-94. DOI: 10.1002/cncy.21338. View

18.

Sato M, Kojima M, Nagatsuma A, Nakamura Y, Saito N, Ochiai A . Optimal fixation for total preanalytic phase evaluation in pathology laboratories: a comprehensive study including immunohistochemistry, DNA, and mRNA assays. Pathol Int. 2014; 64(5):209-16. DOI: 10.1111/pin.12164. View

19.

Chung J, Braunschweig T, Williams R, Guerrero N, Hoffmann K, Kwon M . Factors in tissue handling and processing that impact RNA obtained from formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem. 2008; 56(11):1033-42. PMC: 2569903. DOI: 10.1369/jhc.2008.951863. View